NICE says ‘no’ to regular NHS funding for Roche’s Tecentriq in TNBCNICE has said Roche’s Tecentriq (atezolizumab) should not get regular NHS funding in first draft guidance as a Share XNICE says ‘no’ to regular NHS funding for Roche’s Tecentriq in TNBChttps://pharmaphorum.com/news/nice-says-no-to-regular-nhs-funding-for-roches-tecentriq-in-tnbc/
NICE numbers at 20: trends in dealsNICE provides a downloadable excel file of details of Technology Appraisal (TAs) recommendations which can help explore trends Share XNICE numbers at 20: trends in dealshttps://pharmaphorum.com/views-analysis-market-access/nice-numbers-at-20-trends-in-deals/
Blow to Novartis as NICE rejects migraine drug Aimovig againAfter NICE rejected Novartis’ migraine prevention drug Aimovig in draft guidance issued in January, it was inundated with Share XBlow to Novartis as NICE rejects migraine drug Aimovig againhttps://pharmaphorum.com/news/blow-to-novartis-as-nice-rejects-migraine-drug-aimovig-again/
NICE numbers at 20 – a closer look at cancerThere has been continual interest in what the UK’s Health Technology Assessment (HTA) agency, the National Institute for Share XNICE numbers at 20 – a closer look at cancerhttps://pharmaphorum.com/views-analysis-market-access/nice-numbers-at-20-a-closer-look-at-cancer/
HAE patients get new option as NICE backs Takeda’s TakhzyroPatients in England and Wales with hereditary angioedema (HAE) should soon have a new treatment option after NICE Share XHAE patients get new option as NICE backs Takeda’s Takhzyrohttps://pharmaphorum.com/news/hae-patients-get-new-option-as-nice-backs-takedas-takhzyro/
NHS funds eye gene therapy, after Novartis cuts £613,000 priceNICE has recommended the NHS should fund Novartis’ Luxturna for a rare eye disorder, after the company agreed Share XNHS funds eye gene therapy, after Novartis cuts £613,000 pricehttps://pharmaphorum.com/news/nhs-funds-eye-gene-therapy-after-novartis-cuts-613000-price/
NICE lowers threshold for blood pressure drugs in new guidanceNew guidelines on the management of high blood pressure in the UK will see thousands more patients eligible Share XNICE lowers threshold for blood pressure drugs in new guidancehttps://pharmaphorum.com/news/nice-lowers-threshold-for-blood-pressure-drugs-in-new-guidance/
Who could replace Sir Andrew Dillon at NICE?With Sir Andrew Dillon announcing his retirement as chief executive of NICE, pharmaphorum discusses potential replacements for the Share XWho could replace Sir Andrew Dillon at NICE?https://pharmaphorum.com/views-and-analysis/who-could-replace-sir-andrew-dillon-at-nice/
After two decades taking on pharma over price, Sir Andrew Dillon steps down from NICEAfter more than 20 years of challenging pharma over drug prices, Sir Andrew Dillon is to step down Share XAfter two decades taking on pharma over price, Sir Andrew Dillon steps down from NICEhttps://pharmaphorum.com/news/after-two-decades-taking-on-pharma-over-price-sir-andrew-dillon-steps-down-from-nice/
